News articles about Integra Lifesciences (NASDAQ:IART) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Integra Lifesciences earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the life sciences company an impact score of 46.4270279251637 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Analysts Anticipate Integra lifesciences (IART) to Post $0.60 EPS (americanbankingnews.com)
- Integra lifesciences (IART) versus HTG Molecular Diagnostics (HTGM) Head-To-Head Survey (americanbankingnews.com)
- Free Post Earnings Research Report: Integra’s Quarterly Sales Surged 38%; Adjusted EPS Soared 49% (finance.yahoo.com)
- Notable ETF Inflow Detected – IJR, CHE, HAE, IART (nasdaq.com)
- Integra LifeSciences closes $350m offering (massdevice.com)
A number of research firms have recently issued reports on IART. BidaskClub raised shares of Integra Lifesciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 8th. Oppenheimer set a $70.00 price objective on shares of Integra Lifesciences and gave the stock a “buy” rating in a report on Tuesday, May 1st. ValuEngine raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Friday, April 27th. Zacks Investment Research raised shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $69.00 price objective for the company in a report on Tuesday, May 1st. Finally, Morgan Stanley lifted their price objective on shares of Integra Lifesciences from $53.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, April 26th. Eleven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Integra Lifesciences presently has a consensus rating of “Hold” and an average target price of $59.23.
Integra Lifesciences opened at $64.59 on Monday, Marketbeat reports. The company has a quick ratio of 1.66, a current ratio of 2.53 and a debt-to-equity ratio of 1.77. The firm has a market capitalization of $5.68 billion, a price-to-earnings ratio of 33.29, a price-to-earnings-growth ratio of 1.94 and a beta of 0.66. Integra Lifesciences has a twelve month low of $41.51 and a twelve month high of $65.32.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, April 25th. The life sciences company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.09. The business had revenue of $357.10 million during the quarter, compared to the consensus estimate of $349.15 million. Integra Lifesciences had a net margin of 5.39% and a return on equity of 17.90%. The firm’s revenue for the quarter was up 38.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.39 earnings per share. equities analysts anticipate that Integra Lifesciences will post 2.41 EPS for the current fiscal year.
In other Integra Lifesciences news, Director Christian S. Schade sold 15,658 shares of the business’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $52.88, for a total value of $827,995.04. Following the completion of the sale, the director now directly owns 75,262 shares of the company’s stock, valued at $3,979,854.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Richard E. Caruso sold 32,880 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $53.68, for a total transaction of $1,764,998.40. The disclosure for this sale can be found here. Insiders sold 80,765 shares of company stock valued at $4,376,248 over the last three months. 5.10% of the stock is currently owned by insiders.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.